Vedolizumab (VDZ) is a humanized monoclonal antibody, which specifically binds to human integrin α4β7. Blocking the α4β7 integrin results in gut-selective anti-inflammatory activity. Vedolizumab is indicated for therapy of adult patients with moderate to severe ulcerative colitis (UC) and those with moderate to severe Crohn’s disease (CD). At present, in Slovakia, based on current categorization, vedolizumab is in the first and second line of the biological treatment of UC, but it is only in the second line of biological treatment of CD. Though, selected group CD patient with the serious comorbidity can receive VDZ in the first line. The article describes cases of UC and CD patient treated with vedolizumab in the first and second line.